Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.79 +4.0%	$2.42	$1.11 ▼ $13.38	$52.22M	1.57	385,343 shs	280,914 shs
MDCX Medicus Pharma	$3.03 +2.0%	$3.88	$1.80 ▼ $8.94	$40.31M	N/A	480,196 shs	382,012 shs
NERV Minerva Neurosciences	$2.11 +16.1%	$1.69	$1.15 ▼ $3.38	$12.68M	-0.34	22,659 shs	128,413 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+3.41%	+2.84%	-0.71%	+124.76%	-77.61%
MDCX Medicus Pharma	+2.02%	-8.46%	+13.91%	-24.25%	+302,999,900.00%
NERV Minerva Neurosciences	+16.07%	+22.95%	+18.26%	+31.56%	-37.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	1.5589 of 5 stars	3.5	1.0	0.0	0.6	1.7	0.6
MDCX Medicus Pharma	2.1896 of 5 stars	3.8	0.0	0.0	2.6	1.7	0.0
NERV Minerva Neurosciences	4.226 of 5 stars	3.0	5.0	4.6	2.0	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	3.00	Buy	$18.00	545.86% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	675.58% Upside
NERV Minerva Neurosciences	2.00	Hold	$5.00	137.53% Upside

Current Analyst Ratings Breakdown

Latest NERV, ANVS, and MDCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/12/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $27.00
5/8/2025	MDCX Medicus Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
4/28/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.29 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	$0.24 per share	8.68	($3.67) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.16	N/A	N/A	N/A	N/A	-380.03%	-224.22%	7/17/2025 (Estimated)
NERV Minerva Neurosciences	$1.44M	$0.82	2.57	N/A	N/A	N/A	-20.68%	15.73%	8/5/2025 (Estimated)

Latest NERV, ANVS, and MDCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ANVS Annovis Bio	-$0.36	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	NERV Minerva Neurosciences	-$0.95	N/A	N/A	N/A	N/A	N/A
7/17/2025	N/A	MDCX Medicus Pharma	-$0.39	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
5/13/2025	Q1 2025	NERV Minerva Neurosciences	-$1.07	-$0.50	+$0.57	-$0.50	N/A	N/A
5/12/2025	Q1 2025	MDCX Medicus Pharma	-$0.23	-$0.42	-$0.19	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	10.68	10.68
MDCX Medicus Pharma	N/A	1.53	1.53
NERV Minerva Neurosciences	N/A	9.21	9.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
MDCX Medicus Pharma	N/A
NERV Minerva Neurosciences	34.56%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
MDCX Medicus Pharma	11.20%
NERV Minerva Neurosciences	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
MDCX Medicus Pharma	N/A	13.57 million	12.05 million	N/A
NERV Minerva Neurosciences	9	N/A	N/A	Not Optionable

NERV, ANVS, and MDCX Headlines

Recent News About These Companies

Minerva CEO navigates 'nightmare' lab market to secure new HQ in Woburn

July 16 at 6:03 AM | bizjournals.com

Minerva University Named World's Most Innovative University for Fourth Consecutive Year

July 15 at 9:50 AM | uk.finance.yahoo.com

Free concert on Minerva’s Municipal Park Stage

July 14 at 6:52 PM | morningjournalnews.comM

Helsinki Cup: Minerva Academy in Round-16 with thumping 7-0 win

July 14 at 6:51 PM | msn.com

Minerva narrowly fell short in final, but won hearts with historic Helsinki Cup campaign

July 13, 2025 | english.newsnationtv.comE

Minerva Academy FC: Defying Odds and Dazzling Europe in Helsinki Cup-2025

July 13, 2025 | devdiscourse.comD

Helsinki Cup: Minerva Academy in semi-finals, two Finland clubs eliminated

July 12, 2025 | english.newsnationtv.comE

Minerva Neurosciences Inc. (NERV) Stock Price Today - WSJ

July 11, 2025 | wsj.com

Minerva registers fourth win in Helsinki Cup

July 10, 2025 | msn.com

Helsinki Cup: Minerva Academy logs twin victories

July 10, 2025 | msn.com

Minerva Academy FC's Triumph: An Unstoppable Force in Helsinki Cup 2025

July 10, 2025 | devdiscourse.comD

Helsinki Cup: Minerva registered its fourth win, creating history by winning the match 9-0

July 10, 2025 | news.webindia123.comN

Minerva High School Athletic Hall of Fame announces Class of 2025 members

July 10, 2025 | msn.com

ValCUN installs Minerva metal Additive Manufacturing machine at Johns Hopkins University

July 8, 2025 | metal-am.comM

Minerva Avenue Charting Next Steps Following Sudden Fire

July 8, 2025 | msn.com

Fire destroys popular North Nashville nightclub Minerva Avenue

July 6, 2025 | msn.com

Minerva nights event to include music, food, games

June 27, 2025 | cantonrep.comC

Nordic Capital invests in CRO and CDMO Minerva Imaging

June 11, 2025 | pehub.com

Minerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025 | finanznachrichten.de

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, ANVS, and MDCX Company Descriptions

Annovis Bio NYSE:ANVS

$2.79 +0.11 (+3.99%)

Closing price 07/16/2025 03:59 PM Eastern

Extended Trading

$2.74 -0.04 (-1.51%)

As of 07/16/2025 06:42 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Medicus Pharma NASDAQ:MDCX

$3.03 +0.06 (+2.02%)

As of 07/16/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Minerva Neurosciences NASDAQ:NERV

$2.10 +0.29 (+16.07%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.03 (-1.43%)

As of 07/16/2025 07:51 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time